● Recruiting

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Condition: Locally Advanced or Metastatic Non-Small Cell Lung Cancer · Sponsor: AstraZeneca

PhasePhase 1

Planned participants304

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

DESTINY-Lung03 will investigate the safety and tolerability of trastuzumab deruxtecan in combination with Immunotherapy Agents with and without chemotherapy in patients with HER2 over-expressing non-small cell lung cancer. The efficacy will be also analyzed as a secondary endpoint.

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

AstraZeneca Lung Cancer Study Locator Service · 1-884-432-3892 · az-lcsl@careboxhealth.com

Always discuss trial participation with your own doctor first.

Locations (91)

Research Site	Duarte, California, United States	Withdrawn
Research Site	Newport Beach, California, United States	Withdrawn
Research Site	Orange, California, United States	Recruiting
Research Site	Santa Rosa, California, United States	Withdrawn
Research Site	Westwood, Kansas, United States	Withdrawn
Research Site	Baltimore, Maryland, United States	Recruiting
Research Site	Detroit, Michigan, United States	Withdrawn
Research Site	Buffalo, New York, United States	Withdrawn
Research Site	New York, New York, United States	Withdrawn
Research Site	The Bronx, New York, United States	Withdrawn
Research Site	Houston, Texas, United States	Recruiting
Research Site	Fairfax, Virginia, United States	Recruiting

+ 79 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04686305